Cladribine-based debulking chemotherapy sequential with reduced intensity regimen and post-transplantation maintenance for refractory myeloid leukemia: a prospective phase II clinical trial

Bone Marrow Transplant. 2022 Jun;57(6):1004-1006. doi: 10.1038/s41409-022-01639-0. Epub 2022 Mar 29.

¹ Shanghai Institute of Hematology, Blood & Marrow Transplantation Center, Collaborative Innovation Center of Hematology, Department of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
² Shanghai Clinical Research Center (SCRC), Feng Lin International Centre, Shanghai, China.
³ Shanghai Institute of Hematology, Blood & Marrow Transplantation Center, Collaborative Innovation Center of Hematology, Department of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. jjl12223@rjh.com.cn.
⁴ Shanghai Institute of Hematology, Blood & Marrow Transplantation Center, Collaborative Innovation Center of Hematology, Department of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. hj10709@rjh.com.cn.

^# Contributed equally.

No abstract available

Publication types